Ras, PI(3)K and mTOR signalling controls tumour cell growth
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
All eukaryotic cells coordinate cell growth with the availability of nutrients in their environment. The mTOR protein kinase has emerged as a critical growth-control node, receiving stimulatory signals from Ras and phosphatidylinositol-3-OH kinase (PI(3)K) downstream from growth factors, as well as nutrient inputs in the form of amino-acid, glucose and oxygen availability. Notably, components of the Ras and PI(3)K signalling pathways are mutated in most human cancers. The preponderance of mutations in these interconnected pathways suggests that the loss of growth-control checkpoints and promotion of cell survival in nutrient-limited conditions may be an obligate event in tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
From Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth (2008) · cites this paper as [13]
In the citing paper
“PI3K signaling may be central to linking the common genetic perturbations of cancer, such as RTK mutations and PTEN loss, with altered metabolic processes, including the “lipogenic phenotype” common to many cancers, including GBM (13, 14, 17, 20).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [20]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 8×
“So, the PI(3)K heterodimer is recruited to the membrane to generate local pools of PtdIns(3,4,5)P3.”
BackgroundInfluentialAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914 · cited 1×
“AMPK inhibits mTOR at least in part by the direct phosphorylation of tuberin ( Box 3 ), and cells that lack tuberin retain activated mTORC1 under conditions of low glucose as well as hypoxi”
BackgroundRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 1×
“In addition to loss of RasGAP function, Ras activity is reported to be elevated through reduced expression of a conserved microRNA (let-7) that targets the 3′ untranslated region of H-ras, N-ras and K-ras messenger RNA”
BackgroundHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · cited 1×
“PTEN catalyses removal of the D3 phosphate from PtdIns(3,4,5)P 3 (the reverse of the reaction catalysed by PI(3)K) to limit and ultimately terminate PI(3)K signalling in cell”
BackgroundSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“The existence of the S6K-based negative-feedback loop means that prolonged rapamycin treatment will probably lead to enhanced PI(3)K–AKT activation in some tumours, as has been observed in several tumour cell lines grown in culture, and in tissues from patients in clinical trials of rapamycin analogue”
Background
Cited by
Items 501–600 of 1,006
Sexual dimorphism in glioma glycolysis underlies sex differences in survival
Ippolito, J. E., Yim, A. K., Luo, J. R., Chinnaiyan, P., & Rubin, J. B. (2017) · JCI Insight · doi:10.1172/jci.insight.92142 · Cited by 80
Three-Dimensional Mass Spectrometry Imaging Identifies Lipid Markers of Medulloblastoma Metastasis
Paine, M. R. L., Liu, J., Huang, D., Ellis, S. R., Trede, D., Kobarg, J. H., Heeren, R. M. A., Fernández, F. M., & MacDonald, T. J. (2019) · Scientific Reports · doi:10.1038/s41598-018-38257-0 · Cited by 79
Sayed, R. E., Jamal, L. E., Iskandarani, S. E., Kort, J., Salam, M. A., & Assi, H. I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00510 · Cited by 82
Yassin, N. Y. S., AbouZid, S. F., El-Kalaawy, A. M., Ali, T. M., Almehmadi, M. M., & Ahmed, O. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112409 · Cited by 88
Targeting Ras in myeloid leukemias
Braun, B. S., & Shannon, K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1005 · Cited by 74
Cell Signaling Pathways That Promote Radioresistance of Cancer Cells
Ouellette, M. M., Zhou, S., & Yan, Y. (2022) · Diagnostics · doi:10.3390/diagnostics12030656 · Cited by 83
mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors
Walsh, S., Flanagan, L., Quinn, C., Evoy, D., McDermott, E. W. M., Pierce, A., & Duffy, M. J. (2011) · The Breast · doi:10.1016/j.breast.2011.09.008 · Cited by 79
Tuberous Sclerosis Complex-1 Deficiency Attenuates Diet-Induced Hepatic Lipid Accumulation
Kenerson, H. L., Yeh, M. M., & Yeung, R. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018075 · Cited by 70
“Phosphorylation of TSC2 by Akt, ERK and RSK in response to growth factors results in mTORC1 activation [29].”
BackgroundTranslating nociceptor sensitivity: the role of axonal protein synthesis in nociceptor physiology
Price, T. J., & Géranton, S. M. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06786.x · Cited by 81
“Although mTOR can also be a substrate for phosphorylation via the ERK pathway (Shaw & Cantley, 2006), it is primarily activated downstream of a number of transmembrane receptors and phosphorylated following upstream activation of the phosphoinositol 3 kinase (PI3K)–AKT pathway (Gingras et al.,…”
BackgroundTargeting mTOR signaling in lung cancer
Marinov, M., Fischer, B. E., & Arcaro, A. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.04.002 · Cited by 80
Venkatesan, A. M., Chen, Z., dos Santos, O., Dehnhardt, C. M., Santos, E. D., Ayral‐Kaloustian, S., Mallon, R. G., Hollander, I. J., Feldberg, L. R., Lucas, J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.07.104 · Cited by 78
Li, L., Edgar, B. A., & Grewal, S. (2010) · BMC Cell Biology · doi:10.1186/1471-2121-11-7 · Cited by 84
A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors
Creighton, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210245 · Cited by 73
“The pathway is commonly deregulated in cancer (Morgensztern and McLeod, 2005; Shaw and Cantley, 2006), and clinical trials, including trials at the Phase III stage for breast cancer, are currently underway to test the efficacy of treatment using mTOR antagonists.”
BackgroundFunction of PTEN during the Formation and Maintenance of Neuronal Circuits in the Brain
van Diepen, M. T., & Eickholt, B. J. (2008) · Developmental Neuroscience · doi:10.1159/000109852 · Cited by 71
Regulation of neural stem/progenitor cell maintenance by PI3K and mTOR
Sato, A., Sunayama, J., Matsuda, K., Tachibana, K., Sakurada, K., Tomiyama, A., Kayama, T., & Kitanaka, C. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2009.12.067 · Cited by 79
Cui, W., Leng, B., & Wang, G. (2018) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2018-0277 · Cited by 75
“The PI3K/Akt signaling pathway is a key signaling cascade to promote cell survival (Shaw and Cantley 2006).”
BackgroundmTOR-Dependent Regulation of PHLPP Expression Controls the Rapamycin Sensitivity in Cancer Cells
Liu, J., Stevens, P. D., & Gao, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.183087 · Cited by 73
Pu, X., Hildebrandt, M. A. T., Lu, C., Lin, J. M., Stewart, D. J., Ye, Y., Gu, J. H., Spitz, M. R., & Wu, X. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.04.008 · Cited by 75
Chu, S., Li, L., Singh, H., & Bhatia, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4312 · Cited by 82
“PI3K consists of a regulatory 85-kDa subunit and a catalytic 110-kDa subunit (33).”
BackgroundInfluentialActivation of mTOR signaling pathway contributes to survival of cervical cancer cells
Ji, J., & Zheng, P. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.12.020 · Cited by 71
Prieto, A. L., O’Dell, S., Varnum, B. C., & Lai, C. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.09.047 · Cited by 77
“…Tyro3 activation can regulate protein translation, since activated mTOR can phosphorylate and activate p70S6K, which in turn phosphorylates the S6 ribosomal protein (Shaw and Cantley, 2006). mTOR can also phosphorylate inhibitors of translation such as 4E-BP1, resulting in enhanced translation.”
BackgroundPhosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma
O'Reilly, K. E., Warycha, M. A., Davies, M. A., Rodrik-Outmezguine, V. S., Zhou, X. K., Yee, H. T., Polsky, D., Pavlick, A. C., Rosen, N. X., Bhardwaj, N., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2336 · Cited by 71
Chiang, C.-T., Way, T., & Lin, J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0107 · Cited by 71
“Interest in the regulation of mTOR has increased substantially in recent years largely because of an apparent link between deregulation of translation and cancer cell survival (42).”
BackgroundZaryouh, H., Pauw, I. D., Baysal, H., Peeters, M., Vermorken, J. B., Lardon, F., & Wouters, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21806 · Cited by 72
Enzymatic features of the glucose metabolism in tumor cells
Herling, A., König, M., Bulik, S., & Holzhütter, H. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08174.x · Cited by 75
Chen, G., Tang, C., Shi, X., Lin, C., Fatima, S., Pan, X., Yang, D., Zhang, G., Lü, A., Lin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4376 · Cited by 73
“Akt activates an array of downstream factors through phosphorylation and then regulates cellular metabolism which is rewired in cancer cells [4].”
BackgroundImpaired wound healing results from the dysfunction of the Akt/mTOR pathway in diabetic rats
Huang, H., Cui, W., Qiu, W., Zhu, M., Zhao, R., Zeng, D., Dong, C., Wang, X., Guo, W., Xing, W., et al. (2015) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2015.06.002 · Cited by 72
Rao, Y. K., Wu, A. T. H., Geethangili, M., Huang, M., Chao, W.-J., Wu, C., Deng, W., Yeh, C., & Tzeng, Y. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100318m · Cited by 70
Fokas, E., McKenna, W. G., & Muschel, R. J. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9394-4 · Cited by 75
Dan, H. C., Adli, M., & Baldwin, A. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1232 · Cited by 69
Managing Stomatitis in Patients Treated With Mammalian Target of Rapamycin Inhibitors
Pilotte, A. P., Hohos, M., Polson, K., Huftalen, T. M., & Treister, N. S. (2011) · Clinical journal of oncology nursing · doi:10.1188/11.cjon.e83-e89 · Cited by 72
“mTOR is a serine or threonine kinase that has a key role in integrating intracellular signals necessary for cell growth, proliferation, metabolism, and survival (Bjornsti & Houghton, 2004; Shaw & Cantley, 2006; Yuan, Kay, Berg, & Lebwohl, 2009).”
BackgroundXu, M., Almasi, S., Yang, Y., Yan, C. W., Sterea, A. M., Syeda, A. K. R., Shen, B. Q., Clements, D. R., Huang, P., Gujar, S. A., et al. (2019) · Cell Calcium · doi:10.1016/j.ceca.2019.02.010 · Cited by 72
Li, T., Zhang, L., Cheng, M., Hu, E., Yan, Q., Wu, Y., Luo, W., Su, H., Yu, Z., Guo, X., et al. (2024) · Chinese Medicine · doi:10.1186/s13020-024-01001-0 · Cited by 69
Freudlsperger, C., Horn, D., Weißfuß, S. W., Weichert, W., Weber, K., Saure, D., Sharma, S., Dyckhoff, G., Grabe, N., Plinkert, P. K., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29328 · Cited by 69
“Furthermore, several studies have indicated an important role of PI3K/AKT signaling in the epithelial-stromal interaction.(17,18) As the important role of the tissue architecture and the tumor microenvironment on both the pathogenesis and the acquisition of resistance to radiotherapy are not reflected in classical pri…”
BackgroundE3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6
Zheng, L., Ding, H., Lu, Z., Li, Y., Pan, Y., Ning, T., & Ke, Y. (2008) · Genes to Cells · doi:10.1111/j.1365-2443.2008.01162.x · Cited by 62
“2005; Shaw & Cantley 2006).”
Oncogenic KRAS promotes malignant brain tumors in zebrafish
Ju, B., Chen, W., Orr, B. A., Spitsbergen, J. M., Jia, S., Eden, C., Henson, H. E., & Taylor, M. R. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0288-2 · Cited by 73
“The Ras and PI3K-AKT pathways are interconnected and converge on mTOR signaling to control tumor cell growth [34].”
BackgroundHurvitz, S. A., Kalous, O., Conklin, D. F., Desai, A. J., Dering, J., Anderson, L. A., O’Brien, N. A., Kolarova, T. R., Finn, R. S., Linnartz, R., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3282-x · Cited by 74
Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis
Çakır, M., & Grossman, A. B. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903170675 · Cited by 69
“However, it is not clear whether the Raf/ERK pathway is the most critical mediator of Ras-dependent tumorigenesis in all cell types; several other Ras effectors have been identified [10].”
BackgroundInfluentialSmooth Muscle–like Cells in Pulmonary Lymphangioleiomyomatosis
Krymskaya, V. P. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200705-061vs · Cited by 78
“In addition to PI3K-Akt–dependent inactivating phosphorylation, the activity of the TSC1/TSC2 tumor suppressor complex is also regulated by other upstream kinases, which relay the signals from growth factors, nutrients, and energy levels (Figure 4), including extracellular signal-regulated kinase (ERK) 1/2 (46), and E…”
BackgroundLee, C. K., Marschner, I. C., Simes, R. J., Voysey, M., Egleston, B. L., Hudes, G. R., & SOUZA, P. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3137 · Cited by 73
“5) 0 (0) Treatment with hypoglycemic agents at baseline 20 (10) 19 (9) Treatment with statins during study 2 (1) 23 (11) Treatment with fibrates during study 4 (2) 12 (6) Treatment with hypoglycemic agents during study 1 (0.”
The stress-responsive protein REDD1 and its pathophysiological functions
Kim, J., Kwon, Y., & Kim, Y. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01056-3 · Cited by 255
Melnik, B. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1358 · Cited by 67
Palorini, R., Rasmo, D. D., Gaviraghi, M., Danna, L. S., Signorile, A., Cirulli, C., Chiaradonna, F., Alberghina, L., & Papa, S. (2012) · Oncogene · doi:10.1038/onc.2012.50 · Cited by 70
Misra, U. K., & Pizzo, S. V. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0430-y · Cited by 70
Bilanges, B., Argonza-Barrett, R., Kolesnichenko, M., Skinner, C., Nair, M., Chen, M., & Stokoe, D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02136-06 · Cited by 68
“Several studies demonstrate that pathways from multiple growth factors inhibit TSC1/TSC2 to regulate mTORC1 (66).”
BackgroundHiguchi, T., Todaka, H., Sugiyama, Y., Ono, M., Tamaki, N., Hatano, E., Takezaki, Y., Hanazaki, K., Miwa, T., Lai, S., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.748210 · Cited by 73
“Furthermore, downstream of EGFR signaling is the AKT signaling pathway, which is involved in cell proliferation and apoptosis resistance (30, 31).”
BackgroundYe, Y., Zhong, W., Sun, P., Wang, D., Wang, C., Hu, L., & Qian, J. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.12.051 · Cited by 72
Opel, D., Naumann, I., Schneider, M., Bertele, D., Debatin, K.-M., & Fulda, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2530 · Cited by 65
Wang, S., Wang, C., Chang, L.-M., Zhou, K., Wang, J.-W., Ke, Y., Yang, D., Shi, H., Wang, R., Shi, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12166 · Cited by 68
Modulation of mitochondrial apoptosis by PI3K inhibitors
Fulda, S. (2012) · Mitochondrion · doi:10.1016/j.mito.2012.05.001 · Cited by 70
Shiah, H. ‐., Chen, C. ‐., Dai, C. ‐., Hsiao, C. ‐., Lin, Y. ‐., Su, W. ‐., Chang, J. ‐., Whang‐Peng, J., Lin, P. ‐., Huang, J. ‐., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12132 · Cited by 66
“Mammalian target of rapamycin (mTOR) is a key protein kinase that regulates cell growth, proliferation, metabolism and angiogenesis.(10) Upregulation of mTOR”
BackgroundAngiogenesis in pre-malignant conditions
Menakuru, S. R., Brown, N. J., Staton, C. A., & Reed, M. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604733 · Cited by 67
“Ras activates the MAP kinase pathway, which in turn targets nuclear transcription factors promoting mitogenesis (Shaw and Cantley, 2006).”
BackgroundFischer, B. E., Marinov, M., & Arcaro, A. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.01.006 · Cited by 75
Chakravarti, N., Kadara, H. N., Yoon, D., Shay, J. W., Myers, J. N., Lotan, D., Sonenberg, N., & Lotan, R. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0076 · Cited by 73
Rictor Phosphorylation on the Thr-1135 Site Does Not Require Mammalian Target of Rapamycin Complex 2
Boulbes, D., Chen, C.-H., Shaikenov, T., Agarwal, N. K., Peterson, T. R., Addona, T. A., Keshishian, H., Carr, S. A., Magnuson, M. A., Sabatini, D. M., et al. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0409 · Cited by 66
“Mol Cancer Res; 8(6) June 2010 tion of this important signaling pathway that gives an advantage for cancer cells in proliferation and survival (5, 30).”
BackgroundNaevus sebaceus: a mosaic RASopathy
Aslam, A. M., Salam, A., Griffiths, C. E. M., & McGrath, J. A. (2013) · Clinical and Experimental Dermatology · doi:10.1111/ced.12209 · Cited by 67
Metabolic Reprogramming in Thyroid Carcinoma
Coelho, R. G., Fortunato, R. S., & de Carvalho, D. P. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00082 · Cited by 69
“In many tumors, the constitutive PI3K activation results in increased glycolysis flux (58, 59), and the PI3K/AKT pathway is crucial to translocate GLUT1 from the cytoplasm to the plasma membrane in thyroid cells (53).”
BackgroundWang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01911-5 · Cited by 66
Misra, U. K., & Pizzo, S. V. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22333 · Cited by 70
RetractedPSGL‐1 and mTOR regulate translation of ROCK‐1 and physiological functions of macrophages
Fox, R., Nhan, T. Q., Law, G. L., Morris, D., Liles, W. C., & Schwartz, S. M. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601522 · Cited by 75
“This observation is not totally surprising, as others have reported a rapamycin-sensitive effect on Akt phosphorylation (Sarbassov et al, 2005; Shaw and Cantley, 2006; Vega et al, 2006).”
BackgroundCholine Transporters in Human Lung Adenocarcinoma: Expression and Functional Implications
Wang, T., Li, J., Chen, F., Zhao, Y., He, X., Wan, D., & Gu, J. (2007) · Acta Biochimica et Biophysica Sinica · doi:10.1111/j.1745-7270.2007.00323.x · Cited by 66
Saxe, J. P., Wu, H., Kelly, T. K., Phelps, M. E., Sun, Y. E., Kornblum, H. I., & Huang, J. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.07.016 · Cited by 68
“PTEN is a negative regulator of the PI3K-Akt-mTOR pathway [42].”
Harada, K., Ferdous, T., Harada, T., & Ueyama, Y. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3523 · Cited by 70
“PI3K and mTOR are located up- and down-stream of Akt respectively, and also act as active players (16).”
Palladium-mediated in situ synthesis of an anticancer agent
Indrigo, E., Clavadetscher, J., Chankeshwara, S. V., Lilienkampf, A., & Bradley, M. (2016) · Chemical Communications · doi:10.1039/c6cc08666g · Cited by 66
Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine
Xie, X., Tang, B., Zhou, J., Gao, Q., & Zhang, P.-B. (2013) · Oncology Reports · doi:10.3892/or.2013.2520 · Cited by 66
Wang, K., Huang, W., Sang, X., Wu, X., Shan, Q., Tang, D.-X., Xu, X., & Cao, G. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153191 · Cited by 70
mTOR signaling as a molecular target for the alleviation of Alzheimer's disease pathogenesis
Rapaka, D., Bitra, V. R., Challa, S. R., & Adiukwu, P. C. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105311 · Cited by 70
Mizumoto, Y., Kyo, S., Mori, N., Sakaguchi, J., Ohno, S., Maida, Y., Hashimoto, M., Takakura, M., & Inoue, M. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00445.x · Cited by 65
Xu, C., Zhao, L., Yue, P., Fang, G., Tao, H., Owonikoko, T. K., Ramalingam, S. S., Khuri, F. R., & Sun, S. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.6.16397 · Cited by 68
“Therefore, targeting the PI3K/Akt/mTOR signaling pathway has become an attractive therapeutic strategy.(4,5) In NSCLC, the PI3K/Akt/mTOR signaling pathway is aberrantly activated, largely due to frequent mutations of its upstream regulators including K-Ras, LKB1 and epidermal growth factor receptor (EGFR).”
BackgroundJi, R., Chou, C.-L., Xu, W., Chen, X.-B., Woodward, D. F., & Regan, J. W. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.063933 · Cited by 71
“many types of cancer (Shaw and Cantley, 2006), and our”
BackgroundMalignant glioma drug discovery – targeting protein kinases
Sathornsumetee, S., Vredenburgh, K. A., Lattimore, K. P., & Rich, J. N. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.1.1 · Cited by 66
“In yeast, the TORC1 complex couples transcription, ribosome biogenesis, translation initiation, nutrient uptake and autophagy to the availability of nutrients, whereas TORC2 controls cell polarity and the spatial control of cell growth [86].”
BackgroundWong, H., & Yau, T. C. C. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0311 · Cited by 68
“It is involved in the initiation of ribosomal translation of mRNA into proteins for cell growth, cell cycle progression, and cell metabolism [68].”
BackgroundMallon, R. G., Hollander, I. J., Feldberg, L. R., Lucas, J., Soloveva, V., Venkatesan, A. M., Dehnhardt, C. M., Santos, E. D., Chen, Z., dos Santos, O., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0954 · Cited by 67
“This pathway regulates cell proliferation, growth, survival, and apoptosis (1, 2).”
BackgroundExpression of selected tumor suppressor and oncogenes in endometrium of women with endometriosis
Laudanski, P., Szamatowicz, J., Kowalczuk, O., Kuzmicki, M., Grabowicz, M., & Chyczewski, L. (2009) · Human Reproduction · doi:10.1093/humrep/dep175 · Cited by 66
“In addition to its role in promoting protein synthesis, S6K1 represses the phosphatidylinositol 3-kinase (PI3K) related pathways, whereas different growth factors, mitogens and hormones activate PI3K signaling and consequently mTOR (Shaw and Cantley, 2006).”
BackgroundCutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment
Ovejero, D., Lim, Y. H., Boyce, A. M., Gafni, R. I., McCarthy, E. F., Nguyen, T. A. T., Eichenfield, L. F., DeKlotz, C. M. C., Guthrie, L. C., Tosi, L. L., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3702-8 · Cited by 65
“Neoplastic growth was frequent in our cohort and published reports, which is not unexpected given that RAS mutations are known to lead to unchecked cell proliferation and tumor development [65].”
BackgroundWanigasooriya, K., Tyler, R., Barros-Silva, J. D., Sinha, Y., Ismail, T., & Beggs, A. D. (2020) · Cancers · doi:10.3390/cancers12051278 · Cited by 64
“mTORC1 can also be activated by ERK and RSK via the inhibition of tuberous sclerosis proteins (TSC) 1 or 2 [27,28].”
Workman, P., Clarke, P. A., Guillard, S., & Raynaud, F. I. (2006) · Nature Biotechnology · doi:10.1038/nbt0706-794 · Cited by 78
The Physiology of Phosphoinositides
Sasaki, T., Sasaki, J., Sakai, T., Takasuga, S., & Suzuki, A. (2007) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.30.1599 · Cited by 66
Chen, H., Li, M., Sanchez, E., Soof, C. M., Bujarski, S. E., Ng, N., Cao, J., Hekmati, T., Zahab, B., Nosrati, J. D., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16158 · Cited by 77
“Tribbles homolog 1 (TRIB1) is a linker between MAPK signalling and C/EBP degradation (Shaw & Cantley, 2006; Yokoyama & Nakamura, 2011).”
BackgroundCrumbs proteins in epithelial morphogenesis
Bazellières, E., Assémat, E., Arsanto, J.-P., Bivic, A. L., & Massey‐Harroche, D. (2009) · Frontiers in bioscience · doi:10.2741/3368 · Cited by 67
“The TSC2 pathway controls many cellular features such as cell size, cell survival, apoptosis and cell cycle progression (for a review, see (60-64)).”
BackgroundE4orf1: A Novel Ligand That Improves Glucose Disposal in Cell Culture
Dhurandhar, E. J., Dubuisson, O. S., Mashtalir, N., Krishnapuram, R., Hegde, V. K., & Dhurandhar, N. V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023394 · Cited by 64
“Ras, an important GTP binding protein [18],[19], has been recognized to induce PI3K/AKT pathway[20], or mimic insulin action on glucose transporters Glut4 and Glut1 [21,22].”
Hwang, K., Na, K.-S., Park, D., Choi, K. H., Kim, B.-R., Shim, H., Jeong, E., & Kim, H.-R. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9450-2 · Cited by 71
Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
Agarwala, S. S., & Case, S. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0141 · Cited by 69
Li, X. H., Fu, D., Latif, N., Mullaney, C., Ney, P. H., Mog, S. R., Whitnall, M. H., Srinivasan, V., & Xiao, M. (2010) · Haematologica · doi:10.3324/haematol.2010.026492 · Cited by 64
Javid, H., Mohammadi, F., Zahiri, E., & Hashemy, S. I. (2019) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-019-00697-1 · Cited by 64
“occur at high frequency in cancers [27, 56].”
Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment
Kim, M. J., Lee, S. J., Ryu, J. H., Kim, S. H., Kwon, I. C., & Roberts, T. M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.019 · Cited by 67
Musnier, A., Heitzler, D., Boulo, T., Tesseraud, S., Durand, G., Lécureuil, C., Guillou, H., Poupon, A., Reiter, É., & Crépieux, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0134-z · Cited by 64
“This is consistent with the proliferating state of the cells and to the well-known role of this pathway in cell growth [38].”
BackgroundAmornphimoltham, P., Leelahavanichkul, K., Molinolo, A., Patel, V., & Gutkind, J. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0703 · Cited by 63
The algal polysaccharide ulvan suppresses growth of hepatoma cells
Zhao, C., Lin, G., Wu, D., Liu, D., You, L., Högger, P., Simal‐Gándara, J., Wang, M., da Costa, J. G. M., Marunaka, Y., et al. (2020) · Food Frontiers · doi:10.1002/fft2.13 · Cited by 66
RNF8 Promotes Lung Cancer Tumorigenesis and Chemoresistance by Regulating AKT
Xu, Y., Hu, Y., Xu, T., Yan, K., Zhang, T., Li, Q., Chang, F., Guo, X., Peng, J., Li, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109854 · Cited by 63
Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis
Zhang, F., Cheng, T., & Zhang, S. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03181-w · Cited by 240
Markova, B., Albers, C., Breitenbuecher, F., Melo, J. V., Brümmendorf, T. H., Heidel, F. H., Lipka, D. B., Duyster, J., Huber, C. H., & Fischer, T. (2009) · Oncogene · doi:10.1038/onc.2009.374 · Cited by 70
“…0950-9232/10 $32.00 www.nature.com/onc Sarbassov et al., 2005). mTOR signaling is deregulated in many diseases including cancer and metabolic disorders and is considered an attractive therapeutic target in these diseases (Giles and Albitar, 2005; Easton and Houghton, 2006; Shaw and Cantley, 2006).”
BackgroundInfluentialMultiple mechanisms of soy isoflavones against oxidative stress-induced endothelium injury
Xu, S., Zhong, W., Ghavideldarestani, M., Saurabh, R., Lindow, S. W., & Atkin, S. L. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.04.021 · Cited by 66
Esposito, D. L., Aru, F., Lattanzio, R., Morgano, A., Abbondanza, M., Malekzadeh, R., Bishehsari, F., Valanzano, R., Russo, A. D., Piantelli, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036190 · Cited by 67
Deoxynivalenol induced mouse skin cell proliferation and inflammation via MAPK pathway
Mishra, S., Tripathi, A., Chaudhari, B. P., Dwivedi, P. D., Pandey, H. P., & Das, M. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.06.003 · Cited by 63
Shin, D. M., Zhang, H., Saba, N. F., Chen, A. Y., Nannapaneni, S., Amin, A. R. M. R., Müller, S., Lewis, M. M., Sica, G., Kono, S. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3149 · Cited by 65
“Our observation of downregulation of pS6 (Figure 6), a commonly used readout for mTOR activation (47, 48) in premalignant tissues after the combined treatment brought themTORpathway to our attention.”
Pilot-Storck, F., Chopin, E., Rual, J.-F., Baudot, A., Dobrokhotov, P., Robinson-Rechavi, M., Brun, C., Cusick, M. E., Hill, D. E., Schaeffer, L., et al. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900568-mcp200 · Cited by 57
“tion is implicated in many human diseases (1, 3, 4, 6).”
BackgroundMelnik, B. C., John, S. M., Carrera‐Bastos, P., & Cordain, L. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-74 · Cited by 69
Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2
Liu, K., Park, C., Li, S., Lee, K. W., Liu, H., He, L., Soung, N., Ahn, J. S., Bode, A. M., Dong, Z., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs156 · Cited by 65
α3 Chains of type V collagen regulate breast tumour growth via glypican-1
Huang, G., Ge, G., Izzi, V., & Greenspan, D. S. (2017) · Nature Communications · doi:10.1038/ncomms14351 · Cited by 77
Metadata
- Authors
- Shaw, R. J., & Cantley, L. C.
- Affiliations
- Salk Institute for Biological Studies (US)
- Beth Israel Deaconess Medical Center (US)
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 424-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2144323242
- Cited by
- 2,019
- References
- 86
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 48 · 2023: 68 · 2022: 68 · 2021: 77 · 2020: 91 · 2019: 74 · 2018: 95 · 2017: 99 · 2016: 109 · 2015: 146 · 2014: 119 · 2013: 153 · 2012: 143
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041890)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- Ras signaling, PI3K signaling, mTOR signaling, tumour cell growth, nutrient sensing, amino acids, glucose, oxygen availability, cancer mutations, carcinogenesis, cell survival
- MeSH terms
- Animals, Humans, Neoplasms, Protein Kinases, Signal Transduction, ras Proteins, Phosphatidylinositol 3-Kinases, Cell Growth Processes, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.